Creo Medical Group PLC
LSE:CREO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Creo Medical Group PLC
Total Current Liabilities
Creo Medical Group PLC
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Creo Medical Group PLC
LSE:CREO
|
Total Current Liabilities
£20.5m
|
CAGR 3-Years
1%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
|
Smith & Nephew PLC
LSE:SN
|
Total Current Liabilities
$1.6B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
LivaNova PLC
NASDAQ:LIVN
|
Total Current Liabilities
$808.1m
|
CAGR 3-Years
40%
|
CAGR 5-Years
21%
|
CAGR 10-Years
41%
|
|
|
EKF Diagnostics Holdings PLC
LSE:EKF
|
Total Current Liabilities
£7.4m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-10%
|
|
|
Inspiration Healthcare Group PLC
LSE:IHC
|
Total Current Liabilities
£8.6m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
14%
|
|
|
EMV Capital PLC
LSE:EMVC
|
Total Current Liabilities
£5.1m
|
CAGR 3-Years
40%
|
CAGR 5-Years
37%
|
CAGR 10-Years
15%
|
|
Creo Medical Group PLC
Glance View
Creo Medical Group Plc operates as a medical device company that focuses on surgical endoscopy. The company is headquartered in Chepstow, Monmouthshire/Sir Fynwy and currently employs 245 full-time employees. The company went IPO on 2016-12-09. The firm focuses on the field of surgical endoscopy. The company is focused on the development and commercialization of minimally invasive electrosurgical devices. The firm has developed CROMA, which delivers bipolar radiofrequency (RF) energy for precise localized cutting and focused microwave (MW) energy for controlled coagulation and ablation through a single accessory port. The company has three initial areas of clinical focus, which include in the Gastrointestinal (GI) tract, soft tissue ablation (including but not limited to the liver, pancreas, kidney), and lung interventions for the resection and/or ablation of precancerous and cancerous lesions. The firm has four technology families, which include Speedboat, MicroBlate, SlypSeal and SpydrBlade.
See Also
What is Creo Medical Group PLC's Total Current Liabilities?
Total Current Liabilities
20.5m
GBP
Based on the financial report for Dec 31, 2024, Creo Medical Group PLC's Total Current Liabilities amounts to 20.5m GBP.
What is Creo Medical Group PLC's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
32%
Over the last year, the Total Current Liabilities growth was 107%. The average annual Total Current Liabilities growth rates for Creo Medical Group PLC have been 1% over the past three years , 32% over the past five years .
